Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP

NCT00725231 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

274

Enrollment

OTHER

Sponsor class

Conditions

Peripheral T Cell Lymphoma, Unspecified
Angioimmunoblastic Lymphadenopathy
Extranodal NK/T-cell Lymphoma

Interventions

BIOLOGICAL: alemtuzumab
DRUG: chemotherapy

Sponsor

University of Göttingen

Collaborators

[object Object]
[object Object]